By Dr. R. Ananth, Life Science Leader magazine
As the current storm in global finance continues to test our defenses, it is a safer-than-usual bet that the long-range forecast for most industries will remain uncertain. Once skies begin to clear and more economic stability enters into play, how will things be different? Having led the original westward consolidation in healthcare globalization, what will India’s role become in global pharma’s new economic business model?
I believe the current poor economic climate will continue to favor the acceleration of outsourcing, and perhaps even in greater scope. As large pharma bears the pressures to meet increasingly challenging shareholder expectations amid difficult conditions and also seeks to prioritize their early pipelines, companies are outsourcing more drug development and manufacturing.